A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma
Publication
, Conference
Duska, LR; Petroni, G; Brown, J; Jelovac, D; Moore, KN; McGuire, WP; Darus, CJ; Barroilhet, LM; Secord, AA
Published in: Gynecologic Oncology
October 2020
Duke Scholars
Published In
Gynecologic Oncology
DOI
ISSN
0090-8258
Publication Date
October 2020
Volume
159
Start / End Page
15 / 15
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Duska, L. R., Petroni, G., Brown, J., Jelovac, D., Moore, K. N., McGuire, W. P., … Secord, A. A. (2020). A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. In Gynecologic Oncology (Vol. 159, pp. 15–15). Elsevier BV. https://doi.org/10.1016/j.ygyno.2020.06.028
Duska, L. R., G. Petroni, J. Brown, D. Jelovac, K. N. Moore, W. P. McGuire, C. J. Darus, L. M. Barroilhet, and A. A. Secord. “A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.” In Gynecologic Oncology, 159:15–15. Elsevier BV, 2020. https://doi.org/10.1016/j.ygyno.2020.06.028.
Duska LR, Petroni G, Brown J, Jelovac D, Moore KN, McGuire WP, et al. A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. In: Gynecologic Oncology. Elsevier BV; 2020. p. 15–15.
Duska, L. R., et al. “A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.” Gynecologic Oncology, vol. 159, Elsevier BV, 2020, pp. 15–15. Crossref, doi:10.1016/j.ygyno.2020.06.028.
Duska LR, Petroni G, Brown J, Jelovac D, Moore KN, McGuire WP, Darus CJ, Barroilhet LM, Secord AA. A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecologic Oncology. Elsevier BV; 2020. p. 15–15.
Published In
Gynecologic Oncology
DOI
ISSN
0090-8258
Publication Date
October 2020
Volume
159
Start / End Page
15 / 15
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis